ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gen-Probe Trumps Solvay In Bid For Innogenetics

June 9, 2008 | APPEARED IN VOLUME 86, ISSUE 23

Gen-Probe, a developer of nucleic acid diagnostics for human disease, has launched a bid to acquire Innogenetics, a Belgian molecular diagnostics firm, for $334 million. The offer competes with a deal announced in April by Solvay to acquire Innogenetics for about $280 million. Solvay currently owns 7% of Innogenetics. A Gen-Probe acquisition would create the world's largest stand-alone molecular diagnostics company, with annual sales in excess of $500 million, according to Gen-Probe. A Solvay official tells C&EN that the company "is currently analyzing the new situation and evaluating all the options."

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment